Big Pharma Conversion from Legacy Revenue Management to Innovative ICyte SaaS Platform

IntegriChain was approached by a top-15 pharma manufacturer with 39 in-line therapies covering 73 indications and an additional 12 drugs in phase 3 clinical trials. Most recently, their legacy portfolio is facing significant public policy pressure. Additionally, their overall portfolio has changed with planned launches of next-generation, self-administered specialty drugs which target smaller patient populations, are high-priced, and will face increased payer policy restrictions and require aggressive commercial payer contracting.

This case study highlights how IntegriChain delivered their innovative ICyte Saas Platform to help the manufacturer identify and resolve obstacles.

Download now!

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper